Back to funds
View filing
ADAR1 Capital Management, LLC
hedge fundUpdated 27 days agoManaged by Adar1 Capital Management, Llc • Latest filing Q2 2026
Portfolio value
$2.2B
Q2 2026
Filings
11
Quarterly 13F history
Top-10 concentration
97.4%
Weight of largest holdings
Annualized return
114.6%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 11 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2023 | $279.8M |
| Q1 2024 | $440.8M |
| Q2 2024 | $529.7M |
| Q3 2024 | $614.9M |
| Q4 2024 | $500.4M |
| Q1 2025 | $538.7M |
| Q2 2025 | $652.1M |
| Q3 2025 | $1.1B |
| Q4 2025 | $1.4B |
| Q1 2026 | $1.7B |
| Q2 2026 | $2.2B |
Top holdings
277 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | A AAVXF ABIVAX SA | $240.5M | 1.80M | 11.01% | — |
| 2 | P PB PROTAGONIST THERAPEUTICS INC | $117.8M | 960.9K | 5.39% | — |
| 3 | R ROIV ROIVANT SCIENCES LTD | $111.7M | 3.16M | 5.11% | — |
| 4 | S SPY STATE STR SPDR S&P 500 ETF T | $96.4M | 129.1K | 4.41% | — |
| 5 | I IMVT IMMUNOVANT INC | $89.8M | 2.33M | 4.11% | — |
| 6 | Z ZLAB ZAI LAB LTD | $64M | 3.37M | 2.93% | — |
| 7 | M MGRB AGIOS PHARMACEUTICALS INC | $47.8M | 1.29M | 2.19% | — |
| 8 | C CRNX CRINETICS PHARMACEUTICALS IN | $45.7M | 1.22M | 2.09% | — |
| 9 | ? N/A EA SERIES TRUST | $39.5M | 337.1K | 1.81% | — |
| 10 | C CYTK CYTOKINETICS INC | $39M | 457.9K | 1.79% | — |
| 11 | S SEPN SEPTERNA INC | $31.5M | 940.7K | 1.44% | — |
| 12 | A AVR ANTERIS TECHNOLOGIES GLOBAL | $31M | 3.15M | 1.42% | — |
| 13 | E EIX EDITAS MEDICINE INC | $28.8M | 8.89M | 1.32% | — |
| 14 | D DNLI DENALI THERAPEUTICS INC | $26.5M | 1.03M | 1.21% | — |
| 15 | S SYRE SPYRE THERAPEUTICS INC | $25.2M | 284.0K | 1.15% | — |
| 16 | V VIR VIR BIOTECHNOLOGY INC | $25M | 2.46M | 1.15% | — |
| 17 | P PRAX PRAXIS PRECISION MEDICINES I | $24.9M | 74.3K | 1.14% | — |
| 18 | I INSM INSMED INC | $24.4M | 228.5K | 1.11% | — |
| 19 | C CLDX CELLDEX THERAPEUTICS INC NEW | $23.1M | 619.5K | 1.05% | — |
| 20 | V VIK VIKING THERAPEUTICS INC | $22.4M | 574.0K | 1.02% | — |